COGNITIVE & NOOTROPIC
Frequently asked questions
Plain-language answers to the most common questions about Semax and Selank — drawn from the published literature and labeled clearly where the evidence runs out.
What is Semax?
Semax is a synthetic heptapeptide (seven amino acids) derived from a fragment of the pituitary hormone ACTH. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro. Unlike full ACTH, it does not trigger cortisol release. It was developed at Russian research institutes and has been a registered prescription nasal spray in Russia and Ukraine for stroke recovery and cognitive impairment. Outside those countries it is an unscheduled research chemical with no approved medical use [3][4].
What is Semax peptide used for?
In Russian clinical practice, Semax is prescribed for acute stroke, transient ischemic attacks, and certain forms of cognitive impairment. In the preclinical research literature it has been studied for neurotrophin upregulation (BDNF, NGF), neuroprotection in ischemia models, and anti-amnesic effects [2][3][5]. In nootropic communities it is used anecdotally for focus, mental clarity, and verbal fluency — but these are community reports, not approved or validated indications.
Is Semax a peptide?
Yes. Semax is a synthetic peptide — specifically a heptapeptide (seven amino acids in sequence: Met-Glu-His-Phe-Pro-Gly-Pro). It is derived from the ACTH(4-7) fragment of adrenocorticotropic hormone, with a C-terminal Pro-Gly-Pro extension added to slow enzymatic degradation. Like all research peptides, it is not a supplement, vitamin, or food — it is a synthetic chemical studied in laboratory and clinical settings [4][6].
How does Semax work?
The primary mechanisms documented in animal research are: (1) rapid, region-specific upregulation of BDNF and NGF gene expression and protein levels in the brain, with a specific, reversible binding site identified in rat basal forebrain (KD ~2.4 nM) [3][4]; (2) inhibition of enkephalin-degrading enzymes in human serum in vitro, potentially prolonging endogenous opioid-peptide signaling [7]; and (3) in ischemia models, a broad shift in immune and vascular gene expression that appears to underlie its neuroprotective effect [2]. The intact peptide reaches the brain within minutes of intranasal administration but is degraded rapidly, which may be why effects are reported as short-lived [6].
What is Selank?
Selank (also called TP-7) is a synthetic heptapeptide derived from tuftsin, an endogenous immune peptide. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at Russian research institutes and has been registered as a prescription anxiolytic in Russia for anxiety and asthenic disorders. Outside Russia it is an unscheduled research chemical with no FDA or EMA approval. Selank and Semax are distinct compounds — different sequences, different mechanisms, and different primary research endpoints [8].
What does Selank do?
In animal models, Selank's primary documented effects are reduction of anxiety-related behavior and modulation of GABAergic neurotransmission. It acts as a positive allosteric modulator of GABA receptors [8] and inhibits enzymes that break down enkephalins (endogenous opioid peptides) [7]. It also increases hippocampal BDNF expression in rats [11] and shifts Th1/Th2 immune cytokine balance in human patients with anxiety-asthenic disorders [12]. In nootropic communities it is reported to reduce background anxiety and social anxiety without causing sedation — but these are anecdotal accounts, not clinical claims.
What is Selank peptide used for?
In Russian clinical practice, Selank is prescribed for anxiety and asthenic disorders. In preclinical research it has been studied as a non-benzodiazepine anxiolytic and for its immunomodulatory effects [8][12]. In self-experimenter and nootropic communities it is used anecdotally for situational anxiety reduction — before high-pressure events, public speaking, or difficult conversations — because of its reported fast onset via the intranasal route and its reportedly non-sedating effect profile. These are anecdotal community observations, not validated indications [9].
How does Selank work?
The best-characterized mechanisms are: (1) positive allosteric modulation of GABA receptor binding — Selank modulates [³H]GABA binding to brain membranes in a subtype-selective way that differs from benzodiazepines [8]; (2) inhibition of enkephalin-degrading enzymes, stabilizing endogenous opioid peptides [7]; (3) shifts in GABA-pathway gene expression in rat frontal cortex at one and three hours post-administration [10]; and (4) modulation of hippocampal BDNF expression in vivo [11]. Its tuftsin derivation also gives it an immune-signaling axis, including Th1/Th2 cytokine modulation [12].
Are Semax and Selank the same thing?
No. They are distinct compounds in every pharmacologically meaningful sense. Semax derives from ACTH(4-7) and is primarily a neuroprotective and neurotrophin-upregulating peptide. Selank derives from tuftsin and is primarily an anxiolytic peptide via GABAergic modulation. They share a C-terminal Pro-Gly-Pro tail and a Russian origin, but their amino acid sequences, primary target systems, clinical research endpoints, and community-reported effect profiles are categorically different. Conflating them misrepresents both.
Are Semax and Selank approved drugs?
In Russia and Ukraine, Semax is a registered prescription nasal spray for stroke and cognitive impairment. In Russia, Selank is registered as a prescription anxiolytic. Outside those jurisdictions — including the United States, EU, and UK — neither compound is approved by any regulatory body (FDA, EMA, MHRA, etc.) for any human indication. Both are handled as research chemicals in those markets.
How are these peptides typically studied in research?
Both compounds have been studied primarily by intranasal or intraperitoneal administration in rodent models (rats, mice) at doses expressed in micrograms per kilogram. Semax's mechanistic research has used radiolabeled peptide to measure brain penetration [6] and gene-array techniques to profile transcriptional changes [2][3]. Selank's research has combined receptor-binding assays, gene-expression arrays [10], behavioral anxiety tests [9], and in one case human peripheral-blood immune assays [12]. Consumer-facing research chemicals are not pharmaceutical-grade products and are not manufactured to the standards of the research compounds.
What are the risks of these research peptides?
Key risk factors for both: (1) unregulated supply — identity, purity, and dose are not independently verified for research-chemical products; (2) limited long-term human safety data — almost all experience outside Russia is short-term and anecdotal; (3) complex multi-system pharmacology — both compounds touch neurotrophin, opioid-enkephalin, and monoaminergic pathways, and Selank also touches immune-cytokine signaling, making drug interaction predictions unreliable; (4) no validated human dosing framework exists for either compound outside Russian pharmaceutical formulations [7][8].
Does this site sell Semax or Selank?
No. Peptide Peptalk is a literature digest — a reading desk, not a vendor or clinic. We do not sell compounds, process orders, or direct users to suppliers. Every page on this site describes what the published research says and nothing more.